Crystalline Glycopyrrolate Tosylate

ABSTRACT

Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed.

Glycopyrrolate is a quaternary ammonium cation of the muscarinicanticholinergic group. Glycopyrrolate, typically as a bromide salt, hasbeen used in the treatment of a variety of conditions including diarrhea(U.S. Pat. Nos. 6,214,792 and 5,919,760), urinary incontinence (U.S.Pat. Nos. 6,204,285 and 6,063,808), and anxiety (U.S. Pat. No.5,525,347). Additionally, U.S. Pat. No. 5,976,499 discloses a method fordiagnosing cystic fibrosis in a patient by, in part, stimulating sweatproduction through the injection of a glycopyrrolate solution into apatient. Glycopyrrolate has also been used for the treatment ofhyperhidrosis in US 20100276329.

Glycopyrrolate has previously been made available as a bromide salt oran acetate salt. The bromide salt of glycopyrrolate is sold as Rubinol®.The term “glycopyrrolate” as used in the label for Rubinol® refers tothe bromide salt which is more formally referred to as glycopyrroniumbromide.

SUMMARY OF THE INVENTION

In one aspect of the invention, a salt of glycopyrrolate is providedwherein the anion is selected from benzoate, edisylate, oxalate,hydrogen sulfate, and tosylate.

In a further aspect of the invention, glycopyrrolate tosylate, includingpolymorphs, co-crystals, hydrates and solvates thereof, is provided.

In a further aspect of the invention, solid glycopyrrolate tosylate isprovided, including polymorphs, solvates, hydrates and co-crystalsthereof and amorphous glycopyrrolate tosylate.

In another aspect of the invention, glycopyrrolate tosylate monohydrateis provided.

In a further aspect of the invention, crystalline glycopyrrolatetosylate, including polymorphs, co-crystals, hydrates and solvatesthereof, is provided.

In a yet another aspect of the invention, crystalline glycopyrrolatetosylate monohydrate and polymorphs thereof are provided.

In another aspect of the invention, Form C glycopyrrolate tosylate isprovided.

In a further aspect of the invention, dehydrated crystallineglycopyrrolate tosylate monohydrate, hereinafter referred to asdehydrated Form D, is provided.

In further aspects of the invention, processes for making Forms C and Dof glycopyrrolate tosylate are provided, as are Form C and Form Dglycopyrrolate tosylate made by those processes.

In another aspect of the invention, methods of treating hyperhidrosisusing Forms C or D of glycopyrrolate tosylate are provided.

In another aspect of the invention, amorphous glycopyrrolate tosylate isprovided.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the ORTEP drawing of Form D glycopyrrolate tosylatemonohydrate.

FIG. 2 is an x-ray powder diffraction pattern of Form D glycopyrrolatetosylate monohydrate.

FIG. 3 is an infrared (“IR”) spectrum of Form D glycopyrrolate tosylatemonohydrate.

FIG. 4 is the x-ray powder diffraction pattern of Form C glycopyrrolatetosylate.

FIG. 5 is the IR spectrum of Form C glycopyrrolate tosylate.

FIG. 6 is the indexing solution for Form C glycopyrrolate tosylate withPawley refinement.

FIG. 7 includes a DSC thermogram and TGA for Form C glycopyrrolatetosylate.

FIG. 8 is the x-ray powder diffraction for dehydrated Form Dglycopyrrolate tosylate.

FIG. 9 is an overlay of Form D and dehydrated Form D glycopyrrolatetosylate.

FIG. 10 is the indexing solution for dehydrated Form D glycopyrrolatetosylate with Pawley refinement.

FIG. 11 is the indexing solution for Form D glycopyrrolate tosylatemonohydrate with Pawley refinement.

FIG. 12 is the x-ray powder diffraction for crystalline glycopyrrolatebenzoate.

FIG. 13 is the DSC thermogram for crystalline glycopyrrolate benzoate.

FIG. 14 is the x-ray powder diffraction for crystallinedi-glycopyrrolate edisylate.

FIG. 15 is DSC thermogram for crystalline di-glycopyrrolate edisylate.

FIG. 16 is the x-ray powder diffraction for crystalline glycopyrrolateoxalate.

FIG. 17 is the x-ray powder diffraction for crystalline glycopyrrolatehydrogen sulfate.

FIG. 18 is the DSC thermogram for crystalline glycopyrrolate hydrogensulfate.

FIG. 19 is an x-ray amorphous diffraction pattern of glycopyrrolatetosylate.

FIG. 20 is a DSC/TGA overlay of an x-ray amorphous glycopyrrolatetosylate.

FIG. 21 is the x-ray powder diffraction pattern for glycopyrrolatebromide.

FIG. 22 is the x-ray powder diffraction pattern for glycopyrrolateacetate.

FIG. 23 is the modulated DSC thermogram of an x-ray amorphousglycopyrrolate tosylate.

DETAILED DESCRIPTION OF THE INVENTION

The term “solid form” is often used to refer to a class or type ofsolid-state material. One kind of solid form is a “polymorph” whichrefers to two or more compounds having the same chemical formula butdiffering in solid-state structure. Salts may be polymorphic. Whenpolymorphs are elements, they are termed allotropes. Carbon possessesthe well-known allotropes of graphite, diamond, andbuckminsterfullerene. Polymorphs of molecular compounds, such as activepharmaceutical ingredients (“APIs”), are often prepared and studied inorder to identify compounds meeting scientific or commercial needsincluding, but not limited to, improved solubility, dissolution rate,hygroscopicity, and stability.

Other solid forms include solvates and hydrates of compounds includingsalts. A solvate is a compound wherein a solvent molecule is present inthe crystal structure together with another compound, such as an API.When the solvent is water, the solvent is termed a hydrate. Solvates andhydrates may be stoichiometric or non-stoichiometric. A monohydrate isthe term used when there is one water molecule, stoichiometrically, withrespect to, for example, an API, in the unit cell.

In order to identify the presence of a particular solid form, one ofordinary skill typically uses a suitable analytical technique to collectdata on the form for analysis. For example, chemical identity of solidforms can often be determined with solution-state techniques such as¹³C-NMR or ¹H-NMR spectroscopy and such techniques may also be valuablein determining the stoichiometry and presence of “guests” such as wateror solvent in a hydrate or solvate, respectively. These spectroscopictechniques may also be used to distinguish, for example, solid formswithout water or solvent in the unit cell (often referred to as“anhydrates”), from hydrates or solvates.

Solution-state analytical techniques do not provide information aboutthe solid state as a substance and thus, for example, solid-statetechniques may be used to distinguish among solid forms such asanhydrates. Examples of solid-state techniques which may be used toanalyze and characterize solid forms, including anhydrates and hydrates,include single crystal x-ray diffraction, x-ray powder diffraction(“XRPD”), solid-state ¹³C-NMR, Infrared (“IR”) spectroscopy, Ramanspectroscopy, and thermal techniques such as Differential Scanningcalorimetry (DSC), melting point, and hot stage microscopy.

Polymorphs are a subset of crystalline forms that share the samechemical structure but differ in how the molecules are packed in asolid. When attempting to distinguish polymorphs based on analyticaldata, one looks for data which characterize the form. For example, whenthere are two polymorphs of a compound (e.g., Form I and Form II), onecan use x-ray powder diffraction peaks to characterize the forms whenone finds a peak in a Form I pattern at angles where no such peak ispresent in the Form II pattern. In such a case, that single peak forForm I distinguishes it from Form II and may further act to characterizeForm I. When more forms are present, then the same analysis is also donefor the other polymorphs. Thus, to characterize Form I against the otherpolymorphs, one would look for peaks in Form I at angles where suchpeaks are not present in the x-ray powder diffraction patterns of theother polymorphs. The collection of peaks, or indeed a single peak,which distinguishes Form I from the other known polymorphs is acollection of peaks which may be used to characterize Form I. If, forexample, two peaks characterize a polymorph then those two peaks can beused to identify the presence of that polymorph and hence characterizethe polymorph. Those of ordinary skill in the art will recognize thatthere are often multiple ways, including multiple ways using the sameanalytical technique, to characterize polymorphic polymorphs. Forexample, one may find that three x-ray powder diffraction peakscharacterize a polymorph. Additional peaks could also be used, but arenot necessary, to characterize the polymorph up to and including anentire diffraction pattern. Although all the peaks within an entirediffractogram may be used to characterize a crystalline form, one mayinstead, and typically does as disclosed herein, use a subset of thatdata to characterize such a crystalline form depending on thecircumstances.

When analyzing data to distinguish an anhydrate from a hydrate, forexample, one can rely on the fact that the two solid forms havedifferent chemical structures—one having water in the unit cell and theother not. Thus, this feature alone may be used to distinguish the formsof the compound and it may not be necessary to identify peaks in theanhydrate, for example, which are not present in the hydrate or viceversa.

X-ray powder diffraction patterns are some of the most commonly usedsolid-state analytical techniques used to characterize solid forms. Anx-ray powder diffraction pattern is an x-y graph with °2θ (diffractionangle) on the x-axis and intensity on the y-axis. The peaks within thisplot may be used to characterize a crystalline solid form. The data isoften represented by the position of the peaks on the x-axis rather thanthe intensity of peaks on the y-axis because peak intensity can beparticularly sensitive to sample orientation (see PharmaceuticalAnalysis, Lee & Web, pp. 255-257 (2003)). Thus, intensity is nottypically used by those skilled in the art to characterize solid forms.

As with any data measurement, there is variability in x-ray powderdiffraction data. In addition to the variability in peak intensity,there is also variability in the position of peaks on the x-axis. Thisvariability can, however, typically be accounted for when reporting thepositions of peaks for purposes of characterization. Such variability inthe position of peaks along the x-axis derives from several sources. Onecomes from sample preparation. Samples of the same crystalline material,prepared under different conditions may yield slightly differentdiffractograms. Factors such as particle size, moisture content, solventcontent, and orientation may all affect how a sample diffracts x-rays.Another source of variability comes from instrument parameters.Different x-ray instruments operate using different parameters and thesemay lead to slightly different diffraction patterns from the samecrystalline solid form. Likewise, different software packages processx-ray data differently and this also leads to variability. These andother sources of variability are known to those of ordinary skill in thepharmaceutical arts.

Due to such sources of variability, it is common to recite x-raydiffraction peaks using the word “about” prior to the peak value in °2θwhich presents the data to within 0.1 or 0.2°2θ of the stated peak valuedepending on the circumstances. The x-ray powder diffraction datacorresponding to the solid forms of glycopyrrolate includingglycopyrrolate tosylate of the disclosure were collected on instrumentswhich were routinely calibrated and operated by skilled scientists.Accordingly, the variability associated with these data would beexpected to be closer to ±0.1°2θ than to ±0.2°2θ and indeed likely lessthan 0.1 with the instruments used herein. However, to take into accountthat instruments used elsewhere by those of ordinary skill in the artmay not be so maintained, for example, all x-ray powder diffractionpeaks cited herein have been reported with a variability on the order of±0.2°2θ and are intended to be reported with such a variability wheneverdisclosed herein and are reported in the specification to onesignificant figure after the decimal even though analytical output maysuggest higher precision on its face.

Single-crystal x-ray diffraction provides three-dimensional structuralinformation about the positions of atoms and bonds in a crystal. It isnot always possible or feasible, however, to obtain such a structurefrom a crystal, due to, for example, insufficient crystal size ordifficulty in preparing crystals of sufficient quality forsingle-crystal x-ray diffraction.

X-ray powder diffraction data may also be used, in some circumstances,to determine the crystallographic unit cell of the crystallinestructure. The method by which this is done is called “indexing.”Indexing is the process of determining the size and shape of thecrystallographic unit cell consistent with the peak positions in asuitable x-ray powder diffraction pattern. Indexing provides solutionsfor the three unit cell lengths (a, b, c), three unit cell angles (α, β,γ), and three Miller index labels (h, k, l) for each peak. The lengthsare typically reported in Angstrom units and the angles in degree units.The Miller index labels are unitless integers. Successful indexingindicates that the sample is composed of one crystalline phase and istherefore not a mixture of crystalline phases.

IR spectroscopy is another technique that may be used to characterizesolid forms together with or separately from x-ray powder diffraction.In an IR spectrum, absorbed light is plotted on the x-axis of a graph inthe units of “wavenumber” (cm⁻¹), with intensity on the y-axis.Variation in the position of IR peaks also exists and may be due tosample conditions as well as data collection and processing. The typicalvariability in IR spectra reported herein is on the order of plus orminus 2.0 cm⁻¹. Thus, the use of the word “about” when referencing IRpeaks is meant to include this variability and all IR peaks disclosedherein are intended to be reported with such variability.

Thermal methods are another typical technique to characterize solidforms. Different polymorphs of the same compound often melt at differenttemperatures. Thus, the melting point of a polymorph, as measured bymethods such as capillary melting point, DSC, and hot stage microscopy,alone or in combination with techniques such as x-ray powderdiffraction, IR spectroscopy, or both, may be used to characterizepolymorphs or other solid forms.

As with any analytical technique, melting point determinations are alsosubject to variability. Common sources of variability, in addition toinstrumental variability, are due to colligative properties such as thepresence of other solid forms or other impurities within a sample whosemelting point is being measured.

As used herein, the term “glycopyrrolate” refers to the cation of thesalt containing glycopyrronium. In other words, as used herein,glycopyrrolate and glycopyrronium are used interchangeably. For example,glycopyrrolate tosylate and glycopyrronium tosylate refer to the samesalt.

The present invention provides the tosylate salt of glycopyrrolate or asolvate thereof, including the solution and various solid forms thereof,the process of preparing glycopyrrolate tosylate, and the therapeuticuse of glycopyrrolate tosylate.

By “glycopyrrolate tosylate,” it is meant a tosylate salt ofglycopyrrolate having the chemical name of3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidiniumtosylate, also known as“3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate,” and a structure as shown below:

Furthermore, the term “glycopyrrolate tosylate,” as used herein, unlessotherwise specified explicitly or implicitly, such as a glycopyrrolatetosylate resulting from a glycopyrrolate starting material with specificdiastereomers (e.g., glycopyrrolate bromide used herein which was amixture of R,S and S,R diastereomers), includes any one of the fourdiastereomers listed below as well as any mixture of two, three, or fourof the diastereomers:

-   (R)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium    4-methylbenzenesulfonate;-   (S)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium    4-methylbenzenesulfonate;-   (R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium    4-methylbenzenesulfonate; and-   (S)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium    4-methylbenzenesulfonate.

In one embodiment, “glycopyrrolate tosylate” is(R)-3-(S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. In another embodiment, the “glycopyrrolatetosylate” is(S)-3-(R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. In another embodiment, the “glycopyrrolatetosylate” is(R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. In another embodiment, the “glycopyrrolatetosylate” is(S)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. In yet another embodiment, the “glycopyrrolatetosylate” is a racemic mixture of(R)-3-(S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate and(S)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. In yet another embodiment, the “glycopyrrolatetosylate” is a racemic mixture of(R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate and(S)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium4-methylbenzenesulfonate. The solvate, such as hydrate, of“glycopyrrolate tosylate”, can be a solvate, e.g., a hydrate, of any oneof the four diastereomers listed above or any mixture of two, three, orfour of the diastereomers.

It is to be understood that the invention further includes isotopicsubstitution. For example, deuterated glycopyrrolates are includedwithin the definition of glycopyrrolate.

In one embodiment of the disclosure, a salt of glycopyrrolate isprovided wherein the anion is selected from benzoate, edisylate,oxalate, hydrogen sulfate, and tosylate including hydrates and solvatesthereof. In a further embodiment, a solid salt of glycopyrrolate isprovided wherein the anion is selected from benzoate, edisylate,oxalate, hydrogen sulfate, and tosylate including polymorphs, hydrates,solvates, the corresponding amorphous forms of each salt, andco-crystals thereof.

In a further embodiment, a crystalline salt of glycopyrrolate benzoateis provided. An x-ray powder diffraction pattern substantially the sameas the pattern of FIG. 12 may be used to characterize one embodiment ofcrystalline glycopyrrolate benzoate. A smaller subset of the peaks maybe used to characterize crystalline glycopyrrolate benzoate. Forexample, any one or more of the peaks, for example, at about 8.0, 11.8,16.1, 17.8, 18.8, 20.1, or 23.8°2θ may be used to characterizecrystalline glycopyrrolate benzoate. For example, the peaks at about8.0°2θ and 16.0°2θ may be used to characterize glycopyrrolate benzoate.In another embodiment, a DSC endotherm at about 79° C. as shown in FIG.13 may be used to characterize crystalline glycopyrrolate benzoate.Combinations of x-ray data and DSC data may also be used to characterizeglycopyrrolate benzoate. For example, one or more of the peaks at about8.0, 11.8, 16.1, 17.8, 18.8, 20.1, or 23.8°2θ, such as the peaks atabout 8.0°2θ and 18.8°2θ together with a DSC endotherm at about 79° C.may be used to characterize glycopyrrolate benzoate.

In an additional embodiment, a crystalline salt of di-glycopyrrolateedisylate is provided. An x-ray powder diffraction pattern substantiallythe same as the pattern of FIG. 14 may be used to characterize oneembodiment of crystalline di-glycopyrrolate edisylate. A smaller subsetof the peaks may be used to characterize crystalline di-glycopyrrolateedisylate. For example, any one or more of the peaks, for example, atabout 5.2, 9.2, 10.4, 11.2, 12.9, 15.3, 17.9, 18.6, 20.9, 22.3, or23.7°2θ may be used to characterize crystalline di-glycopyrrolateedisylate. For example, the peaks at about 11.2 and 17.9°2θ may be usedto characterize diglycopyrrolate edisylate. In another embodiment, a DSCendotherm at about 103° C. as shown in FIG. 15 may be used tocharacterize crystalline di-glycopyrrolate edisylate. Combinations ofx-ray data and DSC data may also be used to characterizedi-glycopyrrolate edisylate. For example, in addition, one or more ofthe peaks at about 5.2, 9.2, 10.4, 11.2, 12.9, 15.3, 17.9, 18.6, 20.9,22.3, or 23.7°2θ, such as the peaks at about 11.2 and 17.9°2θ togetherwith a DSC endotherm at about 103° C. may be used to characterizedi-glycopyrrolate edisylate.

In a further embodiment, a crystalline salt of glycopyrrolate oxalate isprovided. An x-ray powder diffraction pattern substantially the same asthe pattern of FIG. 16 may be used to characterize one embodiment ofcrystalline glycopyrrolate oxalate. A smaller subset of the peaks may beused to characterize crystalline glycopyrrolate oxalate. For example,any one or more of the peaks, for example, at about 5.0, 8.4, 10.7, or12.1°2θ may be used to characterize crystalline glycopyrrolate oxalate.For example, the peaks at about 5.0 and 8.4°2θ may be used tocharacterize glycopyrrolate oxalate.

In an additional embodiment, a crystalline salt of glycopyrrolatehydrogen sulfate is provided. An x-ray powder diffraction patternsubstantially the same as the pattern of FIG. 17 may be used tocharacterize one embodiment of crystalline glycopyrrolate hydrogensulfate. A smaller subset of the peaks may be used to characterizecrystalline glycopyrrolate hydrogen sulfate. For example, any one ormore of the peaks, for example, at about 5.6, 13.1, 14.5, 17.2, 18.2,19.9, 20.2, 21.4, 21.6, 22.7, or 28.9°2θ may be used to characterizecrystalline glycopyrrolate hydrogen sulfate. For example, the peaks atabout 5.6 and 13.1°2θ may be used to characterize glycopyrrolatesulfate. In another embodiment, a DSC endotherm at about 160° C. and/ora second endotherm at about 169° C. as shown in FIG. 18 may be used tocharacterize crystalline glycopyrrolate hydrogen sulfate. Combinationsof x-ray data and DSC data may also be used to characterizeglycopyrrolate hydrogen sulfate. For example, in addition, one or moreof the peaks at about 5.6, 13.1, 14.5, 17.2, 18.2, 19.9, 20.2, 21.4,21.6, 22.7, or 28.9, such as the peaks at about 5.6 and 13.1°2θ,together with a DSC endotherm at about 160° C. or a second endotherm atabout 169° C. or both may be used to characterize glycopyrrolatehydrogen sulfate.

In a further embodiment, a crystalline salt of glycopyrrolate acetate isprovided. An x-ray powder diffraction pattern substantially the same asthe pattern of FIG. 22 may be used to characterize one embodiment ofcrystalline glycopyrrolate acetate. A smaller subset of the peaks may beused to characterize crystalline glycopyrrolate acetate. For example,any one or more of the peaks, for example, at about 5.2, 10.4, 10.8,11.3, 12.6, 15.4, 17.5, 19.1, or 23.6°2θ may be used to characterizecrystalline glycopyrrolate acetate. For example, the peaks at about 5.2and 11.3°2θ may be used to characterize glycopyrrolate acetate.

In another embodiment crystalline glycopyrrolate tosylate monohydrate isprovided, also referred to herein as Form D glycopyrrolate tosylate orForm D. Exemplary preparations of Form D glycopyrrolate tosylate includeExamples 8 and 9 herein. The ORTEP drawing of Form D glycopyrrolatetosylate, based on its crystal structure, is set forth in FIG. 1. Thechemical structure of Form D glycopyrrolate is set forth below asFormula I:

The XRPD pattern corresponding to Form D glycopyrrolate tosylate isrepresented by FIG. 1. The crystal structure of the monoclinic Form Dglycopyrrolate tosylate is set forth herein with the crystal data andacquisition parameter provided in Table 1.

TABLE 1 Crystal Data and Data Collection Parameters for GlycopyrrolateTosylate Form D formula C₂₆H₃₇NO₇S formula weight 507.65 space groupP2₁/n (No. 14) a 8.8715(5) Å b 11.5849(7) Å c 25.5323(14) Å β 96.9 deg V2604.9(3) Å³ Z 4 d_(calc), g cm⁻³ 1.294 crystal dimensions, mm 0.23 ×0.20 × 0.18 temperature, K 150. radiation (wavelength, Å) Cu K_(α)(1.54184) monochromator confocal optics linear abs coef, mm⁻¹ 1.479absorption correction applied empirical^(a) transmission factors: min,max 0.592, 0.766 diffractometer Rigaku RAPID-II h, k, l range 0 to 10 0to 13 −31 to 30 2θ range, deg 3.49-140.48 mosaicity, deg 0.76 programsused SHELXTL F₀₀₀ 1088.0 weighting 1/[σ²(F_(o) ²) + (0.1231P)² +0.8250P] where P = (F_(o) ² + 2F_(c) ²)/3 data collected 24514 uniquedata 4024 R_(int) 0.086 data used in refinement 4024 cutoff used inR-factor calculations F_(o) ² > 2.0σ(F_(o) ²) data with I > 2.0σ(I) 3812number of variables 331 largest shift/esd in final cycle 0.00 R(F_(o))0.064 R_(w)(F_(o) ²) 0.185 goodness of fit 1.098 ^(a)Otwinowski, Z.;Minor, W. Methods Enzymol. 1997, 276, 307. ^(b) Flack, H. D. ActaCryst., 1983, A39, 876. ^(c) Hooft, R. W. W., Straver, L. H., and Spek,A. L. J. Appl. Cryst., 2008, 41, 96-103.

Form D glycopyrrolate tosylate was found to be monoclinic with spacegroup P2₁/n. At 150K, the calculated density was found to be 1.294 gramsper cubic centimeter. To two significant figures after the decimal, theunit cell dimensions were determined to be: a equals about 8.87 Å; bequals about 11.58 A; and c equals about 25.53 A, with correspondingunit cell angles of α=90.00°, β=96.9°, and γ=90.00°. The Form D unitcell was found to be racemic with both R,S and S,R diastereomers ofglycopyrrolate in the unit cell.

A pattern substantially the same as the pattern of FIG. 2 may be used tocharacterize Form D glycopyrrolate tosylate. A smaller subset of thepeaks identified in FIG. 2 may instead be used to characterize Form Dglycopyrrolate tosylate. For example, any one or more of peaks at about6.9, 10.3, 12.6, 13.7, 14.9, 15.3, 15.7, 16.4, 17.7, 18.2, or 20.6°2θmay be used to characterize Form D glycopyrrolate tosylate. For example,the single peak at about 6.9 or 10.3 or 12.6, or 20.6°2θ may be used tocharacterize Form D glycopyrrolate tosylate. In another example, peaksat about 6.9 and 10.3°2θ may be used to characterize Form Dglycopyrrolate. In a further example, the peaks at about 6.9, 10.3, and12.6°2θ may be used to characterize Form D glycopyrrolate tosylate. Instill another example, the peaks at about 10.3 and 12.6°2θ characterizeForm D glycopyrrolate tosylate. Table 2 identifies selected peaks fromFIG. 2. Intensity is provided for completeness.

TABLE 2 Selected Peaks from FIG. 2 Diffraction angle °(2θ) d spacing (Å)Intensity (%)  6.87 ± 0.20 12.867 ± 0.385  100 10.26 ± 0.20 8.620 ±0.171 16 12.55 ± 0.20 7.052 ± 0.114 85 13.72 ± 0.20 6.454 ± 0.095 1514.91 ± 0.20 5.943 ± 0.080 29 15.31 ± 0.20 5.788 ± 0.076 18 15.68 ± 0.205.653 ± 0.073 17 16.43 ± 0.20 5.396 ± 0.066 14 17.73 ± 0.20 5.002 ±0.057 19 18.15 ± 0.20 4.888 ± 0.054 25 18.60 ± 0.20 4.770 ± 0.051 5318.82 ± 0.20 4.716 ± 0.050 28 19.59 ± 0.20 4.532 ± 0.046 16 20.21 ± 0.204.395 ± 0.043 26 20.62 ± 0.20 4.307 ± 0.042 63 21.09 ± 0.20 4.212 ±0.040 19 21.63 ± 0.20 4.109 ± 0.038 19 23.50 ± 0.20 3.786 ± 0.032 1425.15 ± 0.20 3.541 ± 0.028 27

Further, Form D glycopyrrolate tosylate is distinguishable from Form Cglycopyrrolate tosylate and the dehydrated form of Form D glycopyrrolatetosylate by the presence of water in the unit cell of Form D and may beso characterized.

Form D glycopyrrolate tosylate may also be characterized by the IRspectrum in FIG. 3. When considering just IR spectroscopy, the entire IRspectrum may be used to characterize Form D glycopyrrolate tosylate or asubset of the spectrum may be so used. For example, any one or more ofpeaks at about 1734, 1196, 1125, 1036, 1013, and 682 cm⁻¹ or others maybe used alone or in combination to characterize Form D glycopyrrolatetosylate. Selected peaks from the IR spectrum in FIG. 3 are set forthbelow in Table 3.

TABLE 3 Selected Peaks in the IR Spectrum of Form D in from FIG. 3 incm⁻¹ 682 703 713 735 750 801 815 850 856 880 908 934 940 954 975 10131024 1036 1075 1084 1125 1139 1155 1182 1196 1230 1265 1281 1312 13201329 1361 1373 1382 1445 1464 1476 1488 1495 1599 1636 1734 2868 29542967 3033 3057 3422 3568

Form D glycopyrrolate tosylate may be characterized by both the IR andXRPD data as set forth herein. For example, Form D glycopyrrolatetosylate may be characterized by one or more XRPD peaks selected from,for example, about 6.9, 10.3, 12.6, 13.7, 14.9, 15.3, 15.7, 16.4, 17.7,18.2, or 20.6°2θ and one or more of the IR peaks selected from, forexample, about 1734, 1196, 1125, 1036, 1013, and 682 cm⁻¹.

Form D may be prepared by several methods. In one method, glycopyrrolatebromide is treated with a metal salt such as silver salt, of tosylate toform a glycopyrrolate salt. In particular Form D glycopyrrolate tosylatemay be prepared by treating Ag-tosylate with glycopyrrolate-X in asuitable solvent to form a slurry; removing the solids from the slurryto obtain a solution; lyophilizing the solution to form a solid;dissolving the solid in a crystallization solvent; and removing thecrystallization solvent to form Form D glycopyrrolate tosylate, whereinX is a halide. Suitable solvents are those that will afford a slurrywhen treating Ag-tosylate with glycopyrrolate-X. An example of asuitable solvent is an alcohol such as isopropanol. A crystallizationsolvent is a solvent, or mixtures thereof, which will dissolvesufficient solid provided after the lyophilizing stage such that whenthe crystallization solvent is removed, Form D glycopyrrolate is theresulting solid. An example of a crystallization solvent is a mixture ofacetonitrile and water. Embodiments include where X is a halide such asiodide or bromide.

In some embodiments, the crystallization solvent is removed by loweringthe temperature of the solid obtained after lyophilizing in solution anddecanting the solvent. In these and other embodiments, an anti-solvent,such as toluene, is added to the solution containing the dissolvedsolid.

Form D glycopyrrolate tosylate may also be prepared by treatingglycopyrrolate-Y and p-toluenesulfonic acid in a suitable solvent;removal of the solvent to form a solid; re-dissolving the solid in acrystallization solvent to form a solution and removing thecrystallization solvent to form Form D glycopyrrolate tosylate wherein Yis an organic anion. An example of Y is acetate.

In some embodiments, an anti-solvent, such as toluene, is added to thesolution containing the dissolved solid.

As disclosed in US 20100276329, glycopyrrolate bromide may be used totreat hyperhidrosis such as by using a wipe containing a solution ofglycopyrrolate bromide. It is the glycopyrrolate cation of the bromidesalt which is the active clinical moiety. Accordingly, glycopyrrolatetosylate may also be used to treat hyperhidrosis in patients such as byadministering a wipe containing glycopyrrolate tosylate in solution.Further, wipes containing one or more of glycopyrrolate benzoate,edisylate, oxalate, or hydrogen sulfate in solution may similarly beused to treat hyperhidrosis in patients.

In another embodiment, crystalline glycopyrrolate tosylate anhydrate isdisclosed, also referred to herein as Form C glycopyrrolate tosylate orForm C. Exemplary preparations of Form C glycopyrrolate tosylate includeExamples 11, 12, and 13 herein.

The x-ray powder diffraction pattern corresponding to Form Cglycopyrrolate tosylate is provided in FIG. 4. The infrared spectrumcorresponding to Form C glycopyrrolate tosylate is provided in FIG. 5.Form C was indexed to determine unit cell dimensions and the indexingsolution is presented as FIG. 6.

An x-ray powder diffraction pattern substantially the same as thepattern of FIG. 4 may be used to characterize Form C glycopyrrolatetosylate. A smaller subset of the peaks identified in FIG. 4 may be usedto characterize Form C glycopyrrolate tosylate. For example, any one ormore of the peaks at about 5.5, 11.0, 11.8, 13.9, 14.9, 17.8, 19.6,20.4, 21.6 and 22.1 °2θ may be used to characterize Form Cglycopyrrolate tosylate. For example, the single peaks at about 5.5 or11.0 or 14.9°2θ may be used to characterize Form C glycopyrrolatetosylate, or any combination of the three. In another example, peaks atabout 5.5 and 11.0°2θ may be used to characterize Form C glycopyrrolate.In a further example, the peaks at about 5.5, 11.0, and 14.9°2θ may beused to characterize Form C glycopyrrolate tosylate. Table 4 identifiesselected peaks from FIG. 4. Further, Form C glycopyrrolate tosylate isdistinguishable from Form D glycopyrrolate tosylate since Form C lackswater in the unit cell. Intensity is provided for completeness.

TABLE 4 Selected Peaks from FIG. 4 Diffraction angle °(2θ) d spacing (Å)Intensity (%)  5.47 ± 0.20 16.168 ± 0.614  100 10.98 ± 0.20 8.057 ±0.149 34 11.82 ± 0.20 7.489 ± 0.128 13 13.87 ± 0.20 6.384 ± 0.093 2014.86 ± 0.20 5.963 ± 0.081 82 17.75 ± 0.20 4.997 ± 0.056 67 17.92 ± 0.204.951 ± 0.055 53 18.12 ± 0.20 4.897 ± 0.054 35 19.60 ± 0.20 4.528 ±0.046 51 20.39 ± 0.20 4.356 ± 0.043 42 21.59 ± 0.20 4.116 ± 0.038 2722.14 ± 0.20 4.014 ± 0.036 26

Form C glycopyrrolate tosylate may also be characterized by the IRspectrum in FIG. 5. When considering just IR spectroscopy, the entire IRspectrum may be used to characterize Form C glycopyrrolate tosylate or asubset of the spectrum may be so used. For example, any one or more ofthe peaks at about 1733, 1236, 1211, 1198, 1186, 1177, 1120, 1032, 1008,and 682 cm⁻¹ or others may be used alone or in combination tocharacterize Form C glycopyrrolate tosylate. Selected peaks from the IRspectrum in FIG. 5 are set forth below in Table 5.

TABLE 5 Selected Peaks from FIG. 5 in cm⁻¹ 682 706 714 742 755 786 801821 849 886 929 938 956 980 1008 1032 1075 1120 1177 1186 1198 1211 12361293 1317 1446 1464 1475 1485 1597 1733 2867 2961 3032

Form C glycopyrrolate tosylate may be characterized by both the IR andXRPD data as set forth herein. For example, Form C glycopyrrolatetosylate may be characterized by one or more XRPD peaks selected from,for example, about 5.5, 11.0, 11.8, 13.9, 14.9, 17.8, 19.6, 20.4, 21.6,and 22.1°2θ and one or more of the IR peaks selected from, for example,1733, 1236, 1211, 1198, 1186, 1177, 1120, 1032, 1008, and 682 cm⁻¹.

Form C may also be characterized by its thermal characteristics. Forexample, Form C exhibits a melting endotherm at about 168° C. whenmeasured with a Tzero™ pan type configuration at a heating rate of 10°C. per minute from −30° C. to 250° C.

Form C may be characterized by its DSC thermogram alone or incombination with the x-ray powder diffraction data, IR data, or both.For example, Form C glycopyrrolate tosylate may be characterized by aDSC thermogram having an endotherm at about 168° C. and the x-ray powderdiffraction pattern of FIG. 4 and the IR spectrum of FIG. 5. However, itis not necessary to use all of these data to characterize Form C whenusing DSC. For example, the single peak at about 5.5°2θ and the DSCendotherm at about 168° C. may be used to characterize Form Cglycopyrrolate tosylate (see FIG. 7). In another example, the peak atabout 168° C. and the IR peak at about 1733 cm⁻¹ may be used tocharacterize Form C glycopyrrolate tosylate. In yet another example, theendotherm at 168° C., the x-ray powder diffraction peak at about 5.5°2θ, and the IR peak at about 1733 cm⁻¹ may be used to characterize FormC glycopyrrolate tosylate.

Form C may be prepared by dehydrating Form D. Alternatively, Form C maybe prepared by dissolving a glycopyrrolate salt such as, for example, atelevated temperatures such as about 50° C. Slow cooling of the solutionto room temperature followed by vacuum filtration and washing in asuitable organic solvent such as acetone results in the formation ofForm C.

In a further embodiment, dehydrated forms of Form D are provided. Anexemplary preparation of dehydrated Form D includes Example 10 herein.In one such embodiment, a dehydrated form of Form D, hereinafterreferred to as dehydrated Form D, is provided wherein there is no waterin the unit cell. An x-ray powder diffraction pattern of dehydrated FormD is provided in FIG. 8. An overlay of the diffraction pattern showingdehydrated Form D and Form D is provided in FIG. 9.

The indexing solution, with a Pawley refinement, to dehydrated Form D ispresented in FIG. 10 and indicates a unit cell which is of the sameproportions, within experimental variation, as with the indexingsolution of Form D, also with a Pawley refinement (FIG. 11) except for aloss of volume, which is consistent with water loss, and which resultsin a smaller unit cell. The indexing solution from FIG. 11 presents a,b, and c parameters which correspond, respectively, to the c, b, and aparameters of the single crystal study (performed at 150 K) as set forthin Table 1.

The overlay pattern from Form D and dehydrated Form D show that thereare some shifts between the two forms and that can also be seen in thecomparison of the peak positions for selected Miller indices as setforth in Table 6 below. The differences in the Miller indices betweenForm D and dehydrated Form D confirm that they are different solidforms.

TABLE 6 Select Miller Indices and Peak Comparisons between Form D andDehydrated Form D h k l Form D (2Θ) Dehydrated (2Θ) Δ 2 0 0 6.848736.74897 −0.09976 1 1 0 8.16348 8.21407 0.05059 2 1 0 10.09605 10.08663−0.00942 1 0 −1 10.22338 10.50517 0.28179 1 0 1 11.02323 11.370500.34727 0 1 1 12.50656 12.83560 0.32904 1 −1 −1 12.63742 12.91262 0.27522 0 2 22.15015 22.85492 0.70477 1 1 2 22.21449 22.92323 0.70874

Dehydrated Form D is further distinguishable from Form D since it lackswater of crystallization whereas Form D is a monohydrate and from Form Cbecause the peaks of dehydrated Form D (an anhydrate) differsubstantially from those in Form C (anhydrate). For example, as Table 6indicates, dehydrated Form D has a peak at about 6.75°2θ whereas theclosest peak from Form C is at about 6.30°2θ, a difference of 0.45°2θ.In addition, the indexing solution for Form C shows the unit cell to betriclinic whereas the unit cell of dehydrated Form D is monoclinic.

In another series of embodiments, variable hydrates, each with differentwater content in between dehydrated Form D and monohydrate Form D isprovided. Such embodiments provide for a continuum of water content inbetween dehydrated Form D and Form D as illustrated with one example inFIG. 9. One would expect that other materials with an intermediate watercontent to generally exhibit x-ray powder diffraction pattern yieldingpeaks which are intermediate between Form D and dehydrated Form D.

In a further embodiment, the amorphous glycopyrrolate tosylate has anx-ray powder diffraction pattern exhibiting a figure substantially thesame as FIG. 19. In another embodiment, the amorphous glycopyrrolatetosylate of the invention has a glass transition temperature onset ofabout 11.6° C. In yet another embodiment, the amorphous glycopyrrolatetosylate of the invention has an x-ray powder diffraction patternsubstantially the same as in FIG. 19 and a glass transition onsettemperature of about 11.6° C. In still an additional embodiment, theamorphous glycopyrrolate tosylate of the invention has an x-ray powderdiffraction pattern exhibiting an amorphous halo but that is notsubstantially similar to that of FIG. 19.

The amorphous glycopyrrolate tosylate of the invention was observed tobe amorphous by X-ray diffraction in that it had contained the“amorphous halo” associated with amorphous solids. Such a material isoften called “x-ray amorphous.” As used herein, “amorphous” whendescribing glycopyrrolate tosylate means amorphous as determined byx-ray powder diffraction such as, for example, as shown in FIG. 19. DSCand thermogravimetric data for an x-ray amorphous form are shown in FIG.20 whereas the modulated DSC thermogram is set forth in FIG. 23.

In another embodiment, the present invention provides a pharmaceuticallyacceptable solution comprising glycopyrrolate tosylate or a solvatethereof and one or more pharmaceutically acceptable additives. Suchadditives may include such co-solvents as ethanol and one or morepharmaceutically acceptable excipients.

In some embodiments, the pharmaceutically acceptable solution isabsorbed onto a carrier. For example, such a carrier may be an absorbentpad suitable for holding such solution when in storage as well as forapplication of the solution to desired areas of skin.

According to the present invention, the absorbent pad can be based oncotton fabric or non-cotton fabric. In one embodiment, the absorbent padis based on synthetic nonwoven fabric, such as nonwoven rayon andpolypropylene fabric. In one embodiment, the absorbent pad is a 75:25rayon and polypropylene pad. The absorbent pad comprising thepharmaceutically acceptable solution can be prepared by contacting a dryabsorbent pad with a pharmaceutically acceptable solution of theinvention. Then the resulting absorbent pad containing apharmaceutically acceptable solution can be applied to the area of thebody to be treated.

In one embodiment, the present invention provides a process of preparinga pharmaceutically acceptable solution of glycopyrrolate tosylate or asolvate thereof. The process comprises dissolving glycopyrrolatetosylate or a solvate thereof in a suitable solvent such as, forexample, an aqueous solution. In some embodiments, the glycopyrrolatetosylate or a solvate to be dissolved is in a crystalline form, such asForm C or Form D. In some embodiments, the glycopyrrolate tosylate or asolvate thereof is in an x-ray amorphous form.

In another embodiment, the suitable solvent is prepared by mixing waterwith ethanol. Then, the glycopyrrolate tosylate or a solvate thereof ismixed with the suitable solution to dissolve the glycopyrrolate tosylateor a solvate thereof in the suitable solution. One or more excipientscan be added either prior to or after the mixing of the glycopyrrolatetosylate or a solvate thereof and the aqueous solvent.

The pharmaceutically acceptable solution of glycopyrrolate tosylate or asolvate thereof is therapeutically useful. For example, thepharmaceutically acceptable solution can be used for treatinghyperhidrosis or reducing sweating in mammals. In one embodiment, thepresent invention provides a method of reducing sweating in a mammal bytopically administering to the skin of the mammal a therapeuticallyeffective amount of a pharmaceutically acceptable solution ofglycopyrrolate tosylate or a solvate thereof. In one embodiment, themammal is a human. The pharmaceutically acceptable solution can beapplied to one or several areas or even the whole body including, butnot limited to, the hands, e.g., palms; axillae; feet, e.g., soles;groin; face, e.g., cheeks and forehead; and trunk, e.g., back andabdomen.

Instrumental Techniques Used in the Examples

X-Ray Powder Diffraction (XRPD)

X-Ray Powder Diffraction (XRPD)—Reflection Geometry

XRPD patterns were collected with a PANalytical X'Pert PRO MPDdiffractometer using an incident beam of Cu Kα radiation produced usinga long, fine-focus source and a nickel filter. The diffractometer wasconfigured using the symmetric Bragg-Brentano geometry. Prior to theanalysis, a silicon specimen (NIST SRM 640d) was analyzed to verify theobserved position of the Si 111 peak is consistent with theNIST-certified position. A specimen of the sample was prepared as athin, circular layer centered on a silicon zero-background substrate.Antiscatter slits (SS) were used to minimize the background generated byair. Soller slits for the incident and diffracted beams were used tominimize broadening from axial divergence. Diffraction patterns werecollected using a scanning position-sensitive detector (X'Celerator)located 240 mm from the sample and Data Collector software v. 2.2b. Thedata acquisition parameters for each pattern were: Cu (1.54059 Å) x-raytube, 45 kV voltage, 40 mA amperage, 3.50-40.00°2θ scan range, 0.017 or0.08°2θ step size, 1835-1947 s collection time, 1.1 or 1.2°/min scanspeed, ⅛° divergence slit (DS), ¼° incident-beam antiscatter slit (SS),0.0 null revolution time.

X-Ray Powder Diffraction (XRPD)—Transmission Geometry

XRPD patterns were collected with a PANalytical X'Pert PRO MPDdiffractometer using an incident beam of Cu radiation produced using anOptix long, fine-focus source. An elliptically graded multilayer mirrorwas used to focus Cu Kα x-rays through the specimen and onto thedetector. Prior to the analysis, a silicon specimen (NIST SRM 640d) wasanalyzed to verify the observed position of the Si 111 peak isconsistent with the NIST-certified position. A specimen of the samplewas sandwiched between 3-μm-thick films and analyzed in transmissiongeometry. A beam stop, short antiscatter extension, and antiscatterknife edge were used to minimize the background generated by air. Sollerslits for the incident and diffracted beams were used to minimizebroadening from axial divergence. Diffraction patterns were collectedusing a scanning position-sensitive detector (X'Celerator) located 240mm from the specimen and Data Collector software v. 2.2b. The dataacquisition parameters for each pattern were: Cu (1.54059 Å) x-ray tube,45 kV voltage, 40 mA amperage, 1.0-39.99°2θ scan range, 0.017°2θ stepsize, 717-721 s collection time, 3.3 or 3.2°/min scan speed, ½°divergence slit (DS), null incident-beam antiscatter slit (SS), 1.0 nullrevolution time.

Variable Temperature X-Ray Powder Diffraction (VT-XRPD)

XRPD patterns were collected with a PANalytical X'Pert PRO MPDdiffractometer using an incident beam of Cu Kα radiation produced usinga long, fine-focus source and a nickel filter. The diffractometer wasconfigured using the symmetric Bragg-Brentano geometry. Data werecollected and analyzed using Data Collector software v. 2.2b. Prior tothe analysis, a silicon specimen (NIST SRM 640d) was analyzed to verifythe Si 111 peak position. A specimen of the sample was packed into anickel-coated copper well. Antiscatter slits (SS) were used to minimizethe background generated by air scattering. Soller slits for theincident and diffracted beams were used to minimize broadening fromaxial divergence. Diffraction patterns were collected using a scanningposition-sensitive detector (X'Celerator) located 240 mm from thesample. The data acquisition parameters for each pattern were: Cu(1.54059 Å) x-ray tube, 45 kV voltage, 40 mA amperage, 3.50-26.00°2θscan range, 0.008°2θ step size, 1869 s collection time, 0.7°/min scanspeed, ⅛° divergence slit (DS), ¼° incident-beam antiscatter slit (SS),0.0 null revolution time.

An Anton Paar TTK 450 stage was used to collect in situ XRPD patterns atnon-ambient temperatures. The sample was heated with a resistance heaterlocated directly under the sample holder, and the temperature wasmonitored with a platinum 100 resistance sensor located directly underthe specimen. The power to the heater was supplied and controlled by anAnton Paar TCU 100 interfaced with Data Collector.

Infrared Spectroscopy (IR)

IR spectra were acquired on Nicolet 6700 Fourier transform infrared(FT-IR) spectrophotometer (Thermo Nicolet) equipped with an Ever-Glomid/far IR source, an extended range potassium bromide (KBr)beamsplitter, and a deuterated triglycine sulfate (DTGS) detector.Wavelength verification was performed using NIST SRM 1921b(polystyrene). An attenuated total reflectance (ATR) accessory(Thunderdome™, Thermo Spectra-Tech), with a germanium (Ge) crystal wasused for data acquisition. Each spectrum represents 256 co-added scanscollected at a spectral resolution of 2 cm-1. A background data set wasacquired with a clean Ge crystal. A Log 1/R (R=reflectance) spectrum wasobtained by taking a ratio of these two data sets against each other.

Differential Scanning Calorimetry (DSC)

DSC was performed using a TA Instruments 2920 differential scanningcalorimeter. Temperature calibration was performed using NIST-traceableindium metal. The sample was placed into an aluminum DSC pan, coveredwith a lid, and the weight was accurately recorded. A weighed aluminumpan configured as the sample pan was placed on the reference side of thecell. Modulated DSC data (see, e.g., FIG. 23) were obtained on a TAInstruments Q2000 differential scanning calorimeter equipped with arefrigerated cooling system (RCS). Temperature calibration was performedusing NIST-traceable indium metal. The sample was placed into analuminum DSC pan, and the weight was accurately recorded. The pan wascovered with a lid perforated with a laser pinhole, and the lid washermetically sealed. A weighed, crimped aluminum pan was placed on thereference side of the cell. Data were obtained using a modulationamplitude of ±1° C. and a 60 second period with an underlying heatingrate of 2° C./minute from −50 to 220° C. The reported glass transitiontemperatures are obtained from the inflection point of the step changein the reversing heat flow versus temperature curve.

Proton Nuclear Magnetic Resonance (1H NMR)

The solution NMR spectra were acquired with a Varian UNITYINOVA-400spectrometer. The samples were prepared by dissolving a small amount ofsample in DMSO-d6 containing TMS.

Pawley Refinement

Indexing and subsequent Pawley refinement provides the most accuratedetermination of unit cell volume and cell parameters from XRPD data.These computations were performed using TOPAS 4.2, 2009, Bruker AXSGmbH, Karlsruhe, Germany. The background was modeled using a 3rd orderChebychev polynomial. Peak shape was modeled using Lorentziancrystallite size broadening and axial divergence was modeled using thefull axial model. Peak positions were allowed to vary by fitting theunit cell parameters. Whole pattern Pawley refinement was performed onall parameters simultaneously to a convergence of 0.001 in χ2.

Thermogravimetric Analysis (TGA)

TG analyses were performed using a TA Instruments 2950 thermogravimetricanalyzer. Temperature calibration was performed using nickel andAlumel™. Each sample was placed in an aluminum pan and inserted into theTG furnace. The furnace was heated under a nitrogen purge. The dataacquisition parameters are displayed above each thermogram in the Datasection of this report. The method code on the thermogram is anabbreviation for the start and end temperature as well as the heatingrate; e.g., 25-350-10 means “from 25 to 350° C., at 10° C./min.”

EXAMPLES Example 1 Salt Screen

Fourteen salts were targeted; however, only six glycopyrrolate saltswere successfully isolated and characterized: acetate, benzoate,edisylate, oxalate, hydrogen sulfate, and tosylate. These salts wereformed either by (1) reaction of glycopyrrolate bromide with silversalts of salt formers, or (2) reaction of glycopyrrolate acetate withsalt former acids.

Example 2 Glycopyrrolate Benzoate

The glycopyrrolate benzoate salt was prepared only once using route (1)from Example 1. Glycopyrrolate benzoate was generated on reactingsaturated aqueous solutions of each glycopyrrolate bromide with silverbenzoate at approximately 92° C., followed by filtration and subsequentlyophilization of the mother liquor. The material was thenrecrystallized in acetone/MTBE (1/2, vol/vol) and sonicated to formwhite crystalline solids. An XRPD pattern associated with this materialis in FIG. 12. Proton NMR showed the presence of equimolar amounts ofthe glycopyrrolate and benzoate species, as well as water. Thermalanalysis of the sample showed a single endotherm with a peak maximum of79° C. in the DSC thermogram concomitant with a 3.5 wt % loss between 25and 80° C. in the TG trace. The weight loss was equivalent toapproximately one mole of water indicating the formation of amonohydrate.

Example 3 Di-Glycopyrrolate Edisylate

Di-glycopyrrolate Edisylate salt was formed using process (2) fromExample 1. A second molar equivalent of glycopyrrolate acetate was addedto the reaction mixture of glycopyrrolate acetate and a minor amount ofsilver acetate and one molar equivalent of 1,2-ethanedisulfonic acid inethyl acetate/isopropanol (83/17, vol/vol). The mixture was stirred forapproximately five minutes before the resulting grey solids wereisolated and dried under vacuum at ambient temperature for one day. Thedried solids were crystalline with a minor amount of silver acetate byXRPD (FIG. 14). The XRPD pattern was successfully indexed whichindicated that the material was composed of a single crystalline phase.Proton NMR spectroscopy confirmed the presence of two moles ofglycopyrrolate per mole of edisylate, and water. Thermal analysis of thesample showed a 3.8 wt % loss between 25 and 95° C. in the TG trace andan endotherm with a peak maximum at 103° C. in the DSC thermogram. Themass loss equates to approximately two moles water indicating adihydrate.

Example 4 Glycopyrrolate Oxalate

Glycopyrrolate oxalate was prepared using process (2) from Example 1.Equimolar amounts of oxalic acid and glycopyrrolate acetate weredissolved in methanol then fast evaporated and dried under vacuum. Theresulting glassy, gel-like material was recrystallized by slurrying inethyl acetate to produce grey solids that were then dried under vacuumbefore analysis by XRPD and proton NMR spectroscopy. The XRPD patterncan be found in FIG. 16.

Example 5 Glycopyrrolate Hydrogen Sulfate

Glycopyrrolate hydrogen sulfate was prepared as a mixture with a traceamount of silver sulfate using process (2) from Example 1. Equimolaramounts of glycopyrrolate acetate and sulfuric acid were stirred inanhydrous ethyl acetate for approximately one day before the resultingmaterial was isolated and dried under vacuum. The solids werecharacterized by XRPD, proton NMR spectroscopy, thermal techniques andelemental analysis. The XRPD pattern was unique and contained a traceamount of silver sulfate (FIG. 17). The XRPD pattern was successfullyindexed except for the silver sulfate peak at 28.35°2θ, indicating thatthe glycopyrrolate hydrogen sulfate salt was composed of a singlecrystalline phase. The silver sulfate was likely formed from the silveracetate present in the glycopyrrolate acetate starting material. The NMRspectrum was consistent with a 1:1 ratio of a glycopyrrolate andhydrogen sulfate. Thermal analysis showed a major sharp endotherm with apeak maximum at 160° C. and a second endotherm with a peak maximum at169° C., and a negligible weight loss of 0.2 wt % between 25 and 180° C.Elemental analysis confirmed the anhydrous salt stoichiometry.

Example 6 Glycopyrrolate Tosylate

In a dark room, silver tosylate (3.5 g) was dissolved in water (˜100 mL)by sonication. The solution was heated to approximately 40° C. andadditional water was added (˜15 mL). An equimolar amount ofglycopyrrolate bromide (5 g) (mixture of R,S and S,R diastereomers) wasadded and immediately resulted in a yellow precipitate. The slurry wasstirred at approximately 40° C. overnight, and then slowly cooled whilestirring to ambient temperature. At ambient temperature, the solids werevacuum filtered and the wet cake was washed three times withapproximately 10 mL of water. The mother liquor was collected andfiltered two times through a 0.2 μm nylon filter with glass microfiber(GMF). A clear solution was observed after filtration and waslyophilized at approximately −50° C. After 6 days, a mixture of white,needle-like and slightly sticky, glassy solids was observed. Toluene(˜20 mL) was added, and the slurry was briefly sonicated and thenstirred at ambient temperature. Additional toluene (˜80 mL) was addedfor easier stirring, and the mixture was allowed to stand at ambientconditions for 1 day. Solids of glycopyrrolate tosylate were collectedby vacuum filtration and vacuum drying at ambient temperature for 1 day.

Example 7 Preparation of Glycopyrrolate Tosylate

A slurry of equimolar amounts of glycopyrrolate acetate andp-toluenesulfonic acid was prepared in isopropanol (1 mL). The mixturewas stirred at ambient temperature. Additional isopropanol (0.5 mL) wasadded to improve stirring, and the mixture was stirred overnight. Solidsof glycopyrrolate tosylate were isolated by vacuum filtration andanalyzed.

Example 8 Preparation of Glycopyrrolate Tosylate Form D

Glycopyrrolate tosylate (1.0569 g) made from Example 6 was dissolved in4 mL ACN/H₂O (50/50 vol/vol) by sonication. The solution was filteredthrough 0.2 μm nylon filter into a clean vial. The solvent was allowedto partially evaporate from an open vial under ambient conditions.Further evaporation was subsequently performed under nitrogen gas flow.A gel resulted which was vacuum dried at 40° C. for 1 day. Toluene (5mL) was added and the mixture was sonicated for approximately 10 minutescausing white solids to precipitate. The mixture was stirred at ambienttemperature for 1 day. The solids were isolated by vacuum filtration andthe wet cake was washed with approximately 10 mL of toluene. The solidswere vacuum dried at ambient temperature for 1 day. After vacuum dryingthe solids were placed in a vial which remained uncapped and placedinside a relative humidity chamber (˜97%). The chamber was placed insidean oven at 41° C. After 6 days, the solids were analyzed by XRPD showingForm D.

Example 9 Single Crystal Preparation of Form D

Glycopyrrolate tosylate (54.9 mg) made from Example 6 was dissolved inEtOAc/DMF (87/13 vol/vol) at approximately 55° C. at 24 mg/ml. Thesolution was hot filtered through a 0.2 μm nylon filter into apre-warmed vial. The vial containing the solution was first placed in adry ice/acetone bath and then in a freezer (approximately −25 to −10°C.). After 3 days, the solution was re-heated to approximately 50° C.and additional EtOAc was added for 96/4 EtOAc/DMF (vol/vol) at 7 mg/ml.The solution was quickly removed from elevated temperature and placed inthe freezer. Solids were isolated by decanting the solvent and dryingthe solids under ambient conditions.

Single Crystal Data Collection

A colorless chunk of C₂₆H₃₇NO₇S [C₇H₇O₃S, C₁₉H₂₈NO₃, H₂O] havingapproximate dimensions of 0.23×0.20×0.18 mm, was mounted on a fiber inrandom orientation. Preliminary examination and data collection wereperformed with Cu Kα radiation (λ=1.54184 Å) on a Rigaku Rapid IIdiffractometer equipped with confocal optics. Refinements were performedusing SHELX97.

Example 10 Preparation of Dehydrated Form D

A mixture of glycopyrrolate tosylate solids, including Form C and FormD, and a trace amount of silver tosylate was kept over P₂O₅ at ambienttemperature for 18 days. The resulting solids were composed of a mixtureof dehydrated Form D with a trace of silver tosylate as shown by XRPDanalysis.

Example 11 Preparation of Form C Glycopyrrolate Tosylate

Glycopyrrolate tosylate Form D, containing trace amounts of Form C andsilver tosylate, was heated on an Anton Paar TTK 450 stage and XRPDpatterns were collected in situ in the range 3.5-26° (2θ). All heatingsteps were at approximately 10° C./min. The stage was heated inincremental steps of 20° C. from 25 to 125° C. At each step, an XRPDpattern was collected over approximately 4 minutes. The stage was thenheated to 135° C. and an XRPD pattern was collected over approximately16 minutes and after heating further to 145° C., a pattern was collectedin approximately 31 minutes. The sample was subsequently cooled to 25°C. at approximately 24° C./min, upon which a final XRPD pattern wascollected over approximately 16 min. The XRPD pattern of this finalpattern was indexed as Form C.

Example 12 Preparation of Form C Glycopyrrolate Tosylate

Glycopyrrolate tosylate Form D from Example 6 was heated to anapproximate temperature in the range 143-149° C. under a continuousnitrogen purge for approximately 3.3 hours. The vial containing thesolids was capped, placed on a lab bench and allowed to cool down toroom temperature. At room temperature, the vial was placed in a jarcontaining P₂O₅. The sample was prepared for XRPD analysis undernitrogen which confirmed production of Form C.

Example 13 Preparation of Form C Glycopyrrolate Tosylate

Glycopyrrolate tosylate (59.5 mg) from Example 6 was dissolved inacetone at approximately 50° C. at 27 mg/ml. The solution was hotfiltered through a 0.2 μm nylon filter into a pre-warmed vial. The vialwas capped and left on the hot plate which was subsequently turned offto allow the sample to cool slowly to ambient temperature. At ambienttemperature the solution was stirred causing white solids toprecipitate. The solids were isolated by vacuum filtration and the wetcake was washed with approximately 2 ml of acetone. XRPD analysisresulted in Form C.

Example 14 Amorphous Glycopyrrolate Tosylate

Glycopyrrolate tosylate from Example 6 was melted and cooled repeatedlyuntil the majority of the solids had the appearance of a glass bymicroscopy. XRPD analysis indicated that the “glassy” sample wasobserved to be amorphous. A 2.2% weight loss was observed by TGA from 25to 250° C. of the amorphous glycopyrrolate tosylate. The onset of theglass transition temperature was measured at 11.6° C.

All examples presented are representative and non-limiting. Theabove-described embodiments may be modified or varied, without departingfrom the invention, as appreciated by those skilled in the art in lightof the above teachings. It is therefore to be understood that, withinthe scope of the claims and their equivalents, the invention may bepracticed otherwise than as specifically described.

What is claimed is:
 1. Crystalline glycopyrrolate tosylate. 2.Crystalline glycopyrrolate tosylate monohydrate.
 3. Form D crystallineglycopyrrolate tosylate monohydrate of claim 2 characterized by an x-raypowder diffraction pattern comprising a peak at about 6.9°2θ.
 4. Form Dcrystalline glycopyrrolate tosylate monohydrate of claim 2 characterizedby an x-ray powder diffraction pattern comprising a peak at about12.6°2θ.
 5. Form D crystalline glycopyrrolate tosylate monohydrate ofclaim 2 characterized by an x-ray powder diffraction pattern comprisingone peak at 6.9°2θ or 12.6°2θ and further comprising one or more peaksat about 10.3, 13.7, 14.9, 15.3, 15.7, 16.4, 17.7, or 18.2 °2θ.
 6. FormD crystalline glycopyrrolate tosylate monohydrate of claim 2characterized by an x-ray powder diffraction pattern comprising one ormore peaks at about 10.3, 13.7, 14.9, 15.3, 15.7, 16.4, 17.7, or18.2°2θ.
 7. Form D crystalline glycopyrrolate tosylate monohydrate ofclaim 2 characterized by an infrared spectrum comprising one or morepeaks at about 1734, 1196, 1125, 1036, 1013, or 682 cm⁻¹.
 8. Form Dcrystalline glycopyrrolate tosylate monohydrate of claim 2 characterizedby (i) an x-ray powder diffraction pattern comprising one or more peaksat about 6.9, 10.3, 12.6, 13.7, 14.9, 15.3, 15.7, 16.4, 17.7, or18.2°2θ; and (ii) an infrared spectrum comprising one or more peaks atabout 1734, 1196, 1125, 1036, 1013, or 682 cm⁻¹.
 9. Form D crystallineglycopyrrolate tosylate monohydrate of claim 2 characterized bysubstantially the same x-ray powder diffraction pattern as in FIG. 2.10. Form D crystalline glycopyrrolate tosylate monohydrate of claim 2characterized by substantially the same infrared spectrum as in FIG. 3.11. Form C crystalline glycopyrrolate tosylate of claim
 1. 12. Form Ccrystalline glycopyrrolate tosylate of claim 11 characterized by x-raypowder diffraction pattern comprising a peak at about 5.5°2θ.
 13. Form Ccrystalline glycopyrrolate tosylate of claim 11 characterized by anx-ray powder diffraction pattern comprising a peak at about 11.0°2θ. 14.Form C crystalline glycopyrrolate tosylate of claim 11 comprising anx-ray powder diffraction pattern comprising two or more peaks at about5.5, 11.0, 11.8, 13.9, 14.9, 17.8, 19.6, 20.4, 21.6 or 22.1°2θ.
 15. FormC crystalline glycopyrrolate tosylate of claim 11 characterized by aninfrared spectrum comprising one or more peaks at about 1733, 1236,1211, 1198, 1186, 1177, 1120, 1032, 1008, or 682 cm⁻¹.
 16. Form Ccrystalline glycopyrrolate tosylate of claim 11 characterized by (i) anx-ray powder diffraction pattern comprising two or more peaks at about5.5, 11.0, 11.8, 13.9, 14.9, 17.8, 19.6, 20.4, 21.6, or 22.1°2θ; and(ii) an infrared spectrum comprising one or more peaks at about 1733,1236, 1211, 1198, 1186, 1177, 1120, 1032, 1008, or 682 cm⁻¹.
 17. Form Ccrystalline glycopyrrolate tosylate of claim 11 characterized bysubstantially the same x-ray powder diffraction pattern as FIG.
 4. 18.Form C crystalline glycopyrrolate tosylate of claim 11 characterized bysubstantially the same infrared spectrum as FIG.
 5. 19. Crystallinedehydrated Form D glycopyrrolate tosylate.
 20. The dehydrated Form Dglycopyrrolate tosylate of claim 19 wherein the x-ray powder diffractionis substantially the same as that of FIG. 8.